Protocol
07-044
Full Title
Phase II Trial of Paclitaxel, Ifosfamide, and Cisplatin in Previously Untreated Intermediate and Poor Risk Germ Cell Tumor Patients
Purpose
The standard treatment for patients with advanced germ cell tumors is a combination of the anticancer drugs bleomycin, etoposide, and cisplatin. In patients whose cancers return after this therapy, a combination of the drugs paclitaxel, ifosfamide, and cisplatin (referred to as TIP) has been found to be effective, and has led to the disappearance of the cancer in many patients.
The purpose of this study is to evaluate the safety and effectiveness of TIP therapy in patients with advanced germ cell tumors when it is given as initial treatment. Patients will receive TIP therapy on an outpatient basis.
Investigator
Eligibility
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have a confirmed diagnosis of an intermediate risk or poor risk germ cell tumor that has not yet been treated with chemotherapy.
- Patients must be age 18 or older.
For more information and to see if you are eligible for this study, please contact Dr. Robert Motzer at 646-422-4312.
Disease(s)
Germ Cell Tumors
Locations
ClinicalTrials.gov
